Completed PHASE3 INTERVENTIONAL 4-arm NCT03930992

Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men (OSZCO)

Efficacy of 4 mg Zoledronic Acid Plus Colaren vs 4mg Zoledronic Acid + Conventional Treatment for Secondary Osteoporosis in HIV Positive and Negative Men

Sponsor: Hospital Civil de Guadalajara

Conditions Secondary Osteoporosis

Interventions Colaren in HIV negative Colaren in HIV positive standard treatment in HIV negative standard treatment in HIV positive

Updated 6 times since 2019 Last updated: Dec 7, 2023 Started: Apr 17, 2019 Primary completion: Oct 31, 2022 Completion: Oct 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03930992, this PHASE3 trial focuses on Secondary Osteoporosis and remains completed. Sponsored by Hospital Civil de Guadalajara, it has been updated 6 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2024 — Jul 2024 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Oct 2021 — Jan 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

May 2019 — Jan 2021 [monthly]

Recruiting PHASE3

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital Civil de Guadalajara
University of Guadalajara

Data source: University of Guadalajara

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guadalajara, Mexico